Restitutio ad integrum

Malk Partners and Integrum ESG Enter Strategic Partnership to Bring Together Best-in-Class ESG Services and Data

Retrieved on: 
Tuesday, December 13, 2022
Professional Services, Environmental, Social and Governance (ESG), Communications, Technology, Software, Finance, Public Relations, Investor Relations, Partner, Benchmarking, Software, SFDR, Partnership, ESG, Software as a service, Multimedia, Lithium, Restitutio ad integrum, Mälk

Malk Partners (Malk), the preeminent advisor for creating value through ESG management and impact investing, and Integrum ESG (Integrum), the leading provider of ESG data, scoring, and benchmarking, have entered a strategic partnership to create the best-in-class ESG solution for private market investment firms.

Key Points: 
  • Malk Partners (Malk), the preeminent advisor for creating value through ESG management and impact investing, and Integrum ESG (Integrum), the leading provider of ESG data, scoring, and benchmarking, have entered a strategic partnership to create the best-in-class ESG solution for private market investment firms.
  • Another major driver of the growing investor demand for ESG data is the rapidly evolving regulatory backdrop.
  • Integrum ESG is a SaaS (Software as a Service) firm that serves buy-side and professional investors, providing completely transparent, objectively-assessed ESG data.
  • Through the Integrum ESG dashboard, investors can assess a company's ESG score, real-time ESG sentiment, and Impact grades with a variety of unique-to-market features.

NYU Langone's Center for Amputation Reconstruction Launches Osseointegration Program with FDA-Approved Implant System

Retrieved on: 
Thursday, December 1, 2022
U.S. News & World Report, Skin, Perception, Amputation, Elective surgery, Food, NYU Langone Health, Orthopedic surgery, Osseointegration, Hospital, Partnership, Physician, Bone, Patient, Rehabilitation, Food and Drug Administration, NYU, Restitutio ad integrum, Surgeon, Quality of life, News, Division, OPRA, Pressure, FDA, Medical device, Dentistry, MD

The two-step surgical procedure was performed by physicians at NYU Langone's Center for Amputation Reconstruction in partnership with Integrum, which developed the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System.

Key Points: 
  • The two-step surgical procedure was performed by physicians at NYU Langone's Center for Amputation Reconstruction in partnership with Integrum, which developed the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System.
  • The OPRA Implant System is the first and only FDA-approved technology for bone-anchored prostheses in the United States.
  • Led by Dr. Ayalon and Jacques H. Hacquebord, MD ,the Center for Amputation Reconstruction now adds osseointegration treatment to its other advanced surgical techniques and prosthetic technologies for individuals experiencing limb loss.
  • Osseointegration is a surgical procedure to permanently implant a titanium device into the bone for direct attachment to an artificial limb.

Integrum Sells MerchantE to Opn

Retrieved on: 
Tuesday, November 15, 2022
Ecosystem, Growth, Commerce, Technology, Merchant services, Acquisition, Siam Commercial Bank, Partnership, Sale, Company, Investment, CEO, Restitutio ad integrum, Toyota, SCB, Solution, Online shopping, Bank

Headquartered in Alpharetta, Georgia, MerchantE serves the complex needs of mid-market B2B customers through unique integrations and end-to-end payment processing capabilities.

Key Points: 
  • Headquartered in Alpharetta, Georgia, MerchantE serves the complex needs of mid-market B2B customers through unique integrations and end-to-end payment processing capabilities.
  • "While we continue to see tremendous opportunity to continue building and growing the MerchantE platform, we and our management team partners believe that joining with Opn presents a compelling opportunity to accelerate the Company's growth and realize unique synergies," said Integrum co-founders Ursula Burns and Tagar Olson.
  • "Given current market conditions and having made substantial progress against our value creation plan, we determined that this is the right time to exit our investment in MerchantE."
  • I am confident that MerchantE and Opn will create a strong partnership together, and I am pleased to welcome the MerchantE team to our combined company."

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

Retrieved on: 
Tuesday, November 1, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pharmacodynamics, CEO, HKEX, ISU, Multinational corporation, Toxic epidermal necrolysis, Mouse, PDAC, Cancer, Research, CD40, Degenerative disease, Hepatotoxicity, Melanoma, Haemophilia B, Restitutio ad integrum, Safety, Immunoglobulin G, Technology, Disease, Patient, Neoplasm, Therapy, KOSDAQ, Pharmaceutical industry

CD40 is a key co-stimulator in adaptive immune responses, said Yeob Hwang, CEO of ISU ABXIS.

Key Points: 
  • CD40 is a key co-stimulator in adaptive immune responses, said Yeob Hwang, CEO of ISU ABXIS.
  • We are glad for the opportunity to utilize Biocytogen/Eucure Biopharmas anti-CD40 antibody (YH003), as it has outstanding efficacy and safety profiles, both preclinically and clinically.
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.
  • Relying on a strong clinical development team with extensive experience, Eucure Biopharma develops innovative drugs to meet clinical needs for patients worldwide.

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

Retrieved on: 
Tuesday, November 1, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Pharmacodynamics, CEO, HKEX, ISU, Multinational corporation, Toxic epidermal necrolysis, Mouse, PDAC, Cancer, Research, CD40, Degenerative disease, Hepatotoxicity, Melanoma, Haemophilia B, Restitutio ad integrum, Safety, Immunoglobulin G, Technology, Disease, Patient, Neoplasm, Therapy, KOSDAQ, Pharmaceutical industry

CD40 is a key co-stimulator in adaptive immune responses, said Yeob Hwang, CEO of ISU ABXIS.

Key Points: 
  • CD40 is a key co-stimulator in adaptive immune responses, said Yeob Hwang, CEO of ISU ABXIS.
  • We are glad for the opportunity to utilize Biocytogen/Eucure Biopharmas anti-CD40 antibody (YH003), as it has outstanding efficacy and safety profiles, both preclinically and clinically.
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.
  • Relying on a strong clinical development team with extensive experience, Eucure Biopharma develops innovative drugs to meet clinical needs for patients worldwide.

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Retrieved on: 
Tuesday, October 18, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Immunoglobulin G, Lymph, Therapy, Neoplasm, MTD, FIH, HKEX, Antibody, Patient, OX40, Research, Restitutio ad integrum, Cancer, Technology, Multinational corporation, Tumor microenvironment, Lung cancer, Prostate, Pharmacokinetics, Adult, Safety, Immunogenic cell death, Damage-associated molecular pattern, Fine chemical, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.

Key Points: 
  • Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.
  • Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.
  • The Syncrovax platform is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumor cancers.
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Immunotherapy Platform

Retrieved on: 
Tuesday, October 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunoglobulin G, Lymph, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Therapy, Achievement, Neoplasm, MTD, FIH, HKEX, Antibody, Patient, OX40, Research, Restitutio ad integrum, Security (finance), Cancer, Securities Act of 1933, Technology, Goal, Tumor microenvironment, Multinational corporation, Lung cancer, Company, Prostate, Industry, Pharmacokinetics, Adult, Immunotherapy, Safety, Phrase, Immunogenic cell death, Damage-associated molecular pattern, Fine chemical, Pharmaceutical industry, Vaccine

Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.

Key Points: 
  • Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.
  • The Syncrovax platform is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumor cancers.
  • "We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen," said Eamonn Hobbs, President and Chief Executive Officer of Syncromune.
  • This license agreement is an important step in the development of our proprietary Syncrovax platform and further supports Syncromunes strategy to maximize our platform to build a sustainable cancer therapeutics company."

Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022

Retrieved on: 
Monday, October 17, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, TCR, BEIC, HKEX, Research, Restitutio ad integrum, Mouse, Multinational corporation, CCR8, ADC, Medication, BeiGene, TNFR2, GPCR, Pharmaceutical industry, Vaccine, Fine chemical, Global Health Innovative Technology Fund

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November 2-4, 2022.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November 2-4, 2022.
  • With this streamlined antibody development capability, the company has established a diverse preclinical and clinical antibody-based drug pipeline .
  • Dr. Vivian Tian, Sr. Director of Biocytogen Europe Innovation Center (BEIC), will give an oral presentation introducing Biocytogens pipeline assets and the progress of Project Integrum, highlighting the progress of several antibody programs, including TNFR2, B7-H3, CCR8, and Siglec-15.
  • Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum.

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, General Health, Pharmaceutical, Health, Immunoglobulin G, Lymph, Therapy, Neoplasm, MTD, FIH, HKEX, Antibody, Patient, OX40, Research, Restitutio ad integrum, Cancer, Technology, Mouse, Tumor microenvironment, Multinational corporation, Lung cancer, Prostate, Pharmacokinetics, Adult, Safety, Immunogenic cell death, Damage-associated molecular pattern, Fine chemical, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.

Key Points: 
  • Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.
  • Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.
  • The Syncrovax platform is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumor cancers.
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.

M2B Funding Corp's Daniel Kordash Raises Big for St. Jude Children's Research Hospital with October 6th Star-Studded Miami Birthday Bash

Retrieved on: 
Wednesday, October 12, 2022
Magnet, MIAMI, Carroll Group, Ce soir, (SCENE) Metrospace, Research, Restitutio ad integrum, Multimedia, DJ, Friends, Marketing, St. Jude Children's Research Hospital, Singani, Apollo Global Management, Solution, Pharmaceutical industry, Nightclub, Jude the Apostle

Exotic cars from Lamborghini Miami lined the entryway as guests arrived to enjoy overflowing Champagne Lallier, Belvedere Vodka cocktails and an endless sushi bar from NOBU.

Key Points: 
  • Exotic cars from Lamborghini Miami lined the entryway as guests arrived to enjoy overflowing Champagne Lallier, Belvedere Vodka cocktails and an endless sushi bar from NOBU.
  • In between sets, the crowd was treated to a special guest performance by acclaimed record producer and artist Scott Storch on the keys.
  • Daniel Kordash, president of M2B Funding Corp., is thrilled with the legacy the event is leaving behind.
  • "In our first year, we quickly hit our lofty goal of $200,000 for St. Jude Children's Research Hospital.